The Diabetic Retinopathy Market is projected to experience a rise in Compound Annual Growth Rate (CAGR) during the forecast period. The growth in market revenue is primarily driven by increase in prevalence of diabetic patients, growing aging population, and increase in awareness about the consequences of uncontrolled diabetes and its complications.
The Diabetic Retinopathy Market Dynamics are anticipated to change in the coming years owing to the improvement in novel treatment options to treat diabetic retinopathy, increasing healthcare spending across the world. Key players in the emerging landscape are Novartis, Kodiak Sciences Inc., Regenxbio, and others.
Despite advancements in treatment options, several unmet needs persist in the management of diabetic retinopathy which include personalized treatment approaches, early diagnosis methods, and comprehensive patient education.
This comprehensive report offers a detailed analysis of Diabetic Retinopathy. The report presents historical and projected epidemiological data covering Total Prevalent Cases of Diabetic Retinopathy, Total Diagnosed Prevalent Cases of Diabetic Retinopathy, Gender-specific Diagnosed Prevalent Cases of Diabetic Retinopathy, Severity-specific Diagnosed Prevalent Cases of Diabetic Retinopathy and Age-specific Diagnosed Prevalent Cases of Diabetic Retinopathy.
In addition to epidemiology, the Diabetic Retinopathy Drugs Market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the Diabetic Retinopathy Drugs Market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020-2034.
The Diabetic Retinopathy Drugs Market Report analyzes the existing treatment practices and unmet medical requirements in Diabetic Retinopathy. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the Diabetic Retinopathy Drugs Market.
Study Period: 2020-2034
Forecast Period: 2024-2034
Geographies Covered
- US
- EU4 (Germany, France, Italy, and Spain)
- The UK
- Japan
Diabetic Retinopathy Epidemiology
- Total Diabetic Retinopathy Prevalent Cases
- Total Diabetic Retinopathy Diagnosed Prevalent Cases
- Diabetic Retinopathy Gender-specific Diagnosed Prevalent Cases
- Diabetic Retinopathy Severity-specific Diagnosed Prevalent Cases
- Diabetic Retinopathy Age-specific Diagnosed Prevalent Cases
Diabetic Retinopathy Drugs Market
- Total Diabetic Retinopathy Market Size
- Diabetic Retinopathy Market Size by Therapies
Diabetic Retinopathy Drugs Market Analysis
- Conjoint Analysis
- SWOT Analysis
- Diabetic Retinopathy Unmet Needs
Diabetic Retinopathy Companies
- Genentech, Inc. (Roche)
- Regeneron
- Novartis
- Kodiak Sciences
Future Opportunity
The Diabetic Retinopathy Drugs Market holds promise due to rising diabetes prevalence, demand for effective treatments, advancing medical technologies, introduction of novel therapies, and increasing awareness of Diabetic Retinopathy management.
Diabetic Retinopathy Treatment Market
Diabetic retinopathy is a diabetes complication that affects the eyes, caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It can lead to vision impairment and blindness if left untreated. Early detection and management, including regular eye exams and blood sugar control, are crucial for preventing severe vision loss. The main factor related to the development and progression of diabetic retinopathy is poor blood sugar control. Consistently high blood sugar levels damage the blood vessels in the retina, leading to the onset and worsening of the condition. As per the historical data from 2020-2022, the treatment paradigm has already seen significant changes. Going forward key players are developing therapies to overcome the existing unmet needs of the patients.
Diabetic Retinopathy Diagnosis and Treatment Algorithm
Diabetic retinopathy is diagnosed through a comprehensive eye examination, often starting with a dilated eye exam where an ophthalmologist uses special drops to widen the pupil and examine the retina for any damage. During this exam, signs of blood vessel changes, such as leakage or abnormal growths, which are indicative of retinopathy are analyzed. Additional diagnostic tools like fluorescein angiography or optical coherence tomography (OCT) may be employed to capture detailed images of the retina and assess the extent of damage. Early detection through regular eye exams is crucial, as diabetic retinopathy can progress without symptoms until significant damage has occurred.
Current diabetic retinopathy treatment are predominantly focused on addressing macular edema, a common complication. Traditional therapies like vitrectomy, photocoagulation, and corticosteroids, historically utilized, lack the potential for vision enhancement and are associated with significant complication rates. However, in recent years, anti-vascular endothelial growth factor (anti-VEGF) drugs have emerged as a promising advancement in managing diabetic macular edema (DME). While these drugs have substantially improved outcomes for many DME patients, they may not be effective for all cases, particularly in those who have undergone multiple treatments
Therapies for diabetic retinopathy include laser surgery to seal leaking blood vessels, anti-VEGF injections to reduce swelling and inhibit abnormal vessel growth, and vitrectomy to remove the vitreous gel and blood. Effective management of blood sugar, blood pressure, and cholesterol is crucial to complement these treatments.
Diabetic Retinopathy Epidemiology
The epidemiology section on the Diabetic Retinopathy drugs market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the Diabetic Retinopathy Prevalence. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
- Diabetic retinopathy is a major neurovascular complication of diabetes, leading to blindness in working-age adults. According to the American Academy of Ophthalmology, with a global diabetes burden of 387 million people, expected to rise to 592 million by 2035, Diabetic Retinopathy affects 93 million worldwide. Its prevalence is 77.3% in type 1 diabetes and 25.1% in type 2 diabetes, with approximately 25-30% at risk of diabetic macular edema. Lifetime risk estimates range from 50-60% in type 2 diabetes to over 90% in type 1 diabetes.
- According to a meta-analysis on Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045, there are approximately 93 million patients suffering with Diabetic Retinopathy, 17 million patients with proliferative Diabetic Retinopathy, and 21 million patients with diabetic macular edema, worldwide. These data highlight the significant global public health burden of Diabetic Retinopathy.
- As per the insights, in a large-scale study in the United States found that men have a 50% higher prevalence of diabetic retinopathy compared to women among patients over 40 years old. However, some studies suggest that females may have a higher prevalence of Diabetic Retinopathy in certain populations, particularly among those with type 2 diabetes.
- According to research conducted by the American Academy of Ophthalmology, the occurrence of diabetic retinopathy among individuals aged 60 and above is most prominent in France, closely trailed by Germany.
- According to secondary research, at any given point, 15-30% of the diabetic population suffers from some form of diabetic retinopathy. Approximately half of the patients are unaware of their condition due to lack of symptoms and mild non-proliferative disease that might go undetected. Although diabetic retinopathy - through diabetic macular edema and proliferative diabetic retinopathy - is the leading cause of vision loss among working-age populations in the US and many other countries, much of the causative ophthalmic pathology is treatable.
Diabetic Retinopathy Market Outlook
LUCENTIS: Genentech, Inc.
LUCENTIS is a vascular endothelial growth factor (VEGF) inhibitor that blocks VEGF from inside the eye. It is administered by intravitreal injection into the eye once a month, typically every 28 days. LUCENTIS is an FDA-approved prescription medicine for diabetic retinopathy and diabetic macular edema (DME), being the first to receive approval for all forms of diabetic retinopathy, with or without DME, in 2017, after initial approval in 2015.
EYLEA (aflibercept): Regeneron, Inc.
EYLEA was approved by the FDA for the treatment of diabetic retinopathy in 2019. This approval marked the first time a VEGF inhibitor was approved for all stages of DR, including diabetic macular edema (DME), to reduce the risk of blindness. EYLEA is the only VEGF inhibitor approved with two dosing options for DR, allowing doctors to customize treatment to their patients' needs. With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to the publisher, the Diabetic Retinopathy market in the 7MM is projected to grow significantly during the study period 2020-2034.
Emerging Diabetic Retinopathy Drugs
ABBV-RGX-314: Regenxbio
ABBV-RGX-314 is being investigated as a potential one-time treatment for diabetic retinopathy, wet AMD, and other chronic retinal conditions. ABBV-RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit VEGF. ABBV-RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the fluid accumulation in the retina. It is currently in Phase II of its clinical development.
Tarcocimab tedromer: Kodiak Sciences Inc.
Tarcocimab tedromer (KSI-301) is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform. KSI-301 is given as an intravitreal injection and is expected to inhibit VEGF for up to 6 months continuously. The unique properties of KSI-301 are intended to provide patients with long-term control of DME and improve visual results while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to prevent and reverse the progression of DR with long-term efficacy and may reduce the risk of vision-threatening complications from diabetic retinopathy. It is currently in Phase III of its clinical development.
Diabetic Retinopathy Drugs Market Segmentation
The report provides a detailed outlook of the current and future Diabetic Retinopathy Therapeutics Market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future Diabetic Retinopathy Market Share of all therapies.
Diabetic Retinopathy Market Size by Countries
The Diabetic Retinopathy Market Size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) Diabetic Retinopathy Therapeutics Market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Diabetic Retinopathy Market Size by Therapies
Diabetic Retinopathy Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034. One of the emerging drugs anticipated to launch during the forecast period is Tarcocimab Tedromer under the developmental pipeline of Kodiak Sciences Inc.
Diabetic Retinopathy Drugs Uptake
This section focuses on the sales uptake of potential Diabetic Retinopathy drugs that have recently been launched or are anticipated to be launched in the Diabetic Retinopathy market between 2020 and 2034. It estimates the market penetration of Diabetic Retinopathy drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Diabetic Retinopathy Therapeutics Market.
Diabetic Retinopathy Therapeutics Market Access and Reimbursement
The report provides a descriptive overview of the market access and reimbursement scenario of Diabetic Retinopathy. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current Diabetic Retinopathy market trends and fill gaps in secondary findings, we interview KOLs and SMEs working in the Diabetic Retinopathy domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Diabetic Retinopathy market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market of Diabetic Retinopathy unmet needs.
Diabetic Retinopathy: KOL Insights
The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Department of Pathology, University of California, San Diego, US, American Academy of Ophthalmology, Annapolis, MD, United States, Palo Alto Medical Foundation, US, Department of Ophthalmology, University of Bonn, Germany, Department of Medical Biometry, Informatics and Epidemiology, Germany, Department of Ophthalmology, Hospital Universitario y Politécnico La Fe, Spain, Department of Ophthalmology, The Jikei University School of Medicine, Japan, Department of Preventive Medicine, School of Medicine, Japan, Omiya City Clinic, Saitama, Japan and others.
“The rising prevalence of Diabetic Retinopathy and awareness regarding its early diagnosis plays a key factor impacting Diabetic Retinopathy market.”
Competitive Intelligence Analysis
We conduct a Competitive and Diabetic Retinopathy Therapeutics Market Intelligence analysis of the Diabetic Retinopathy Market, utilizing various Competitive Intelligence tools such as SWOT analysis, Conjoint Analysis, and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics. The emerging Diabetic Retinopathy therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Diabetic Retinopathy market.
Diabetic Retinopathy Pipeline Development Activities
The Diabetic Retinopathy Therapeutics Market Report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Diabetic Retinopathy. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The Diabetic Retinopathy pipeline segment report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Diabetic Retinopathy.
Diabetic Retinopathy Therapeutics Market Report Insights
- Patient-based Diabetic Retinopathy Market Forecasting
- Diabetic Retinopathy Therapeutic Approaches
- Diabetic Retinopathy Pipeline Analysis
- Diabetic Retinopathy Market Size and Trends
- Diabetic Retinopathy Therapeutics Market Opportunities
- Impact of Upcoming Diabetic Retinopathy Therapies
Diabetic Retinopathy Therapeutics Market Report Key Strengths
- 11 Years Diabetic Retinopathy Market Forecast
- The 7MM Coverage
- Diabetic Retinopathy Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Diabetic Retinopathy Therapeutics Market
- Diabetic Retinopathy Drugs Uptake
Diabetic Retinopathy Therapeutics Market Report Assessment
- Current Diabetic Retinopathy Treatment Market Practices
- Current Unmet Needs
- Diabetic Retinopathy Pipeline Product Profiles
- Diabetic Retinopathy Therapeutics Market Attractiveness
Key Questions Answered in the Report
- How common is Diabetic Retinopathy?
- What are the key findings of Diabetic Retinopathy epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
- What are the currently available treatments for Diabetic Retinopathy?
- What is the disease risk, burden, and Diabetic Retinopathy Unmet Needs?
- At what CAGR is the Diabetic Retinopathy Treatment Market and its epidemiology expected to grow in the 7MM during the forecast period (2024-2034)?
- How would the unmet needs impact the Diabetic Retinopathy market dynamics and subsequently influence the analysis of the related trends?
- What would be the forecasted patient pool of Diabetic Retinopathy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024-2034)?
- How many companies are currently developing therapies for the Diabetic Retinopathy Treatment?
Table of Contents
1. Key Insights2. Report Introduction
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Genentech, Inc.
- Regeneron Pharmaceuticals
- Roche
- Opthea Limited
- Regenxbio
- Kodiak Sciences Inc.
- Ocuphire Pharma
- Eisai Co. Ltd.
- Apexian Pharmaceuticals
- Oculis
- Bayer
- Novartis Pharmaceuticals
- Allegro Ophthalmics, LLC
- Adverum Biotechnologies, Inc.
- Graybug Vision
- Kubota Vision Inc.
- KalVista Pharmaceuticals Ltd.
